Myocardial InfarctionEarly Phase 1TAKEmedsNCT02597205
The Adherence and Knowledge Exchange Heart and Stroke Medicines Study
A Early Phase 1 study testing physician-facing app and patient-facing messages in people with Myocardial Infarction, run by Duke Kunshan University at 2 sites in China.
Trial summary
The overarching goal of this program to increase the use of evidence-based, secondary-prevention medications and promote healthy lifestyles among myocardial infarction (MI) patients through using provider-facing mobile app and patients-facing text messages. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myocardial Infarction
- What is being tested?
- physician-facing app and patient-facing messages
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 190 participants
- Where
- 2 sitesChina
- Study dates
- May 2015to Jun 2016
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Physicians who: 1) manage MI patients; 2) are interested in and consent to participate in this project; 3) have an Android-based smart phone;
- Patients who: 1) if they have suffered from a myocardial infraction; 2) they are physical and mentally able to manage their MI conditions; 3) they own a mobile telephone with the ability to read text messages or receive voice messages, and 4) willing to provide informed consent.
Who cannot join
- Physicians who i) do not have an Android smart phone or not being able to use one; ii) do not managing MI patients; iii) current participating in another study.
- Patients who are: 1) not being able to use a cellphone; 2) severally ill; 3) current participating in another study.
Trial locations and contacts
2 sites in 1 country.
China2 sites
Hainan Nongken General Hospital
Haikou, Hainan, 570100
Shanghai Xietu Street Community Healthcare Center
Shanghai, Shanghai Municipality, 200000
About this study
Official title: TAKEmeds Program: The Adherence and Knowledge Exchange Heart and Stroke Medicines Study
The overarching goal of this program to increase the use of evidence-based, secondary-prevention medications and promote healthy lifestyles among myocardial infarction (MI) patients through using provider-facing mobile app and patients-facing text messages.
Read the detailed description
Background:
Cardiovascular disease (CVD) affects half of all individuals over their lifetime.CVD is the leading cause of all non-communicable disease (NCD) deaths, and is projected to increase by 15% worldwide between 2010 and 2020. A wealth of evidence and international guidelines support the use of low-cost, evidence-based medication, for the management of established CVD.
Study aim:
- To develop and test the usability of a multifaceted, information-technology intervention among patients with a history of myocardial infarction (MI) and their healthcare providers.
- To develop, contextualize and assess the efficacy of patient-directed text messages as a means of improving medication adherence among myocardial Infraction patients in Shanghai, China.
- To test the usability and efficacy of text message reminders aimed at modifying major health risk behaviors including smoking and diet among MI patients.
Methods:
Study design overview:
This is a short-term, quasi-experimental, pre-post intervention study designed to evaluate the feasibility and effectiveness of using mobile phone app and text messaging as a means to improve adherence to medication for secondary prevention, promote behavior change, and reduce risk factors among MI patients.
Study setting and study team:
The study is going to be conducted in Shanghai and Haikou, Hainan, China. There are four academic collaborating institutions in this study: Global Health Research Center, Duke Kunshan University (DKU), China, Population Health Research Institution (PHRI), Canada and School of Public Health, Fudan University, China and Hainan Nongken General Hospital, China.
The DKU research team plays the leading role to design the study, develop the app and messages and oversee the entire implementation process. The PHRI research team will primarily work with the DKU research team on the physician-facing app and patient-facing messages development. The Fudan and Hainan research team will be responsible for local implementation.
Pre-intervention preparation:
Development of provider software application: To understand the actual needs and barriers that physicians face in using the app, the DKU research team will conduct assessment among physicians in the three community healthcare centers. The assessment is done through a short survey and key informant interview. Information from the survey and interviews will inform app design and development decisions.
Development of patient-centered message bank: The DKU research team will work with the PHRI research team to develop the message bank through literature review search. The message bank will cover five domains to help MI patients with medical adherence and lifestyle modification: 1) medical adherence; 2) diet; 3) exercise; 4) smoking cessation; 5) general heart health (see appendix 4 for the messages). To contextualize the messages and ensure its comprehensibility to patients, the Fudan and Hainan research team will invite physicians to validate the message (see appendix 5 for the message validation survey). Physicians will be asked to score each message in terms of its likability and comprehensibility. Two messages in each domain with the lowest score will be deleted. Considering that reading texts might be difficult for some patients, voice message option is also available for patients to choose. The contents of both the texts and voice messages are identical.
Intervention:
The study is designed to have two interventions targeting physicians and patients respectively. Only one community healthcare center will receive the intervention and the intervention period is designed to be 12 weeks. The Fudan and Hainan research team will be responsible for recruiting physicians and each physician will recruit MI patients to participate in the study. Physicians play dual role in this study: 1) as subjects who will use the app to prescribe medications and 2) as collaborators who will help recruit patients and collect their baseline data. The DKU research team will train the physicians how to use the app before they start to recruit patients.
- Provider-level intervention: Physicians will use the smart phone application, specifically designed for this study, to help them with medications prescription and patient recruitment. The prescription recommendations are based on the NICE (National Institute for Health and Care Excellence) guidelines 2014 in MI secondary prevention.
- Patient-level intervention:
Patients that are eligible to participate will receive automated, periodic evidence-based text messages about consistent medication use and lifestyle modification via text-messaging. They will receive standard ongoing care as well as regular unidirectional text messages via text or voice message over a 12 week period.
Process Evaluation:
Qualitative research methods will be used to obtain feedback from both the providers and the patients on the physician app and the short messaging system (SMS). To assess whether the intervention is implemented as planned and to gain their user feedback, the DKU, Fudan and Hainan research team will conduct phone and face-to-face interviews respectively in the middle and at the end of the intervention. All questions will be open-ended allowing participants to raise important issues even if they are not covered in our original topic guide. Four physicians and eight patients (two from each physician) will be invited to participate in the process evaluation interview. The mid-term evaluation (between 4-6 weeks after the intervention begins) are all one-on-one in-depth interviews. The final-term evaluation will consist of one focus group discussion among the four physicians and individual interviews to patients.
Data management and analysis:
Questionnaires require translation before coding and further data analysis can occur. In addition to coding and translation, interviews and focus groups will both be recorded and require transcription. All data entry will be performed by the Fudan and Hainan research team and will occur as close to the time of data collection to ensure accuracy.
Descriptive analysis will be used to describe the rate of adherence among the patients. Percentage differences in the proportion of patients who adhered to medication use and those who did not adhere to the medication use will be compared. Characteristics will be compared at baseline and after follow-up by using independent t tests for continuous variables (physical activity and diet) or chi-square tests for categorical variables (smoking status). Analyses will be performed using stata, version 12. Lastly, the interview and focus groups transcriptions will be coded for emerging themes using QSR Nvivo.
Risks and benefits:
This study offers participants the prospect of direct benefits: 1) it may potentially improve patient medical adherence; 2) it may potentially help patients build healthy lifestyle; 3) it may give guidance for physicians on evidence-based medicines prescription; 4) it may facilitate interactions between patients and physicians.
No foreseeable risks are anticipated for physicians. As for patients, one concern is that the exercise promotion messages, if taken without cautions, may to some degree increase the risk of heart attack for some patients. To eliminate this concern, the text messages suggest patients consult their doctors first before taking any exercise to reduce such risk to minimal. The risk of possible breach of confidentiality is addressed through using vigorous methods to protect the identity of subjects. After the data are collected, entered, and digitized, the investigators will store identifiable information in a separate data set and remove all such information from the main database (same to the information collected at the pre-intervention stage). The app will generate a unique identification number (ID) for each physician and patient for confidentiality use. Linkage will be through the study ID and performed only when necessary. Baseline and follow-up surveys will be linked by study ID only. As for the information collected on the app, they cannot be accessed without entering the password set by the physicians themselves. Only physicians, programmers and DKU research team members have access to it when necessary.
- Conditions
- Myocardial Infarction
- Being tested
- physician-facing app and patient-facing messages
- Keywords
- Medical adherence, Lifestyle modification, Mobile Health, Secondary Prevention
- Medical subject headings
- Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
physician-facing app and patient-facing messagesBehavioural
A physician-facing app was designed to help physicians with recruiting and managing patients and with evidence-based medications prescription. Messages were also developed to send to patients to improve their medical adherence and modify lifestyle.
| Study group | Role | What they receive |
|---|---|---|
| Mobile app | Experimental | Multi-faceted intervention for physicians and patients respectively: physician-facing app and patient-facing messages Receives: Behavioral: physician-facing app and patient-facing messages |
What is being measured
The primary outcome is the main question the study is designed to answer.
Medical adherence change
Score change measured by the well-validated 4-item Morisky Green Levine Scale
Measured: Three months
Secondary outcomes (3)
Change in diet
Measured by the BRFSS: Fruit and Vegetable Module
Measured: Three months
Change in exercise
Measured by the International Physical Activity Questionnaire
Measured: Three months
Change in smoking habit
Measured by the Tobacco Questions for Surveys, World Health Organization
Measured: Three months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2015 (estimated)
- Study startMay 2015
- Primary completionDec 2015
- Study completionJun 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (16)Papers the sponsor has linked to this study.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 190 participants (actual)
Sponsor and investigators
- Lead sponsor
- Duke Kunshan University
- Sponsor type
- University, hospital or other
- Collaborators
- Population Health Research Institute, Fudan University, Hainan Provincial Nongken General Hospital
- Responsible party
- Sponsor
- Investigators
- JD Schwalm, MD, Principal investigator, Population Health Research Institute, Hamilton Health Sciences Corporation, Canada
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02597205
- Sponsor's protocol ID
- 2014HHSC0016
- Acronym
- TAKEmeds
- Status last verified
- Aug 2018
- First submitted
- 19 Jun 2015
- Last updated
- 27 Aug 2018
- Results posted
- No
- Data monitoring committee
- No
Publications
Selected leading causes of death.: Statistics Canada; 2005.
Global Status Report on Non-Communicable Diseases 2010. Geneva World Health Organization; 2011.
Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006 Feb 14;113(6):791-8. doi: 10.1161/CIRCULATIONAHA.105.548206. Epub 2006 Feb 6.
PubMed 16461820Alwan A, Maclean DR, Riley LM, d'Espaignet ET, Mathers CD, Stevens GA, Bettcher D. Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries. Lancet. 2010 Nov 27;376(9755):1861-8. doi: 10.1016/S0140-6736(10)61853-3. Epub 2010 Nov 10.
PubMed 21074258Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001 Nov 27;104(22):2746-53. doi: 10.1161/hc4601.099487.
PubMed 11723030Lee DS, Chiu M, Manuel DG, Tu K, Wang X, Austin PC, Mattern MY, Mitiku TF, Svenson LW, Putnam W, Flanagan WM, Tu JV; Canadian Cardiovascular Outcomes Research Team. Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors. CMAJ. 2009 Aug 4;181(3-4):E55-66. doi: 10.1503/cmaj.081629. Epub 2009 Jul 20.
PubMed 19620271Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011 Oct 1;378(9798):1231-43. doi: 10.1016/S0140-6736(11)61215-4. Epub 2011 Aug 26.
PubMed 21872920Tu JV, Donovan LR, Lee DS, Wang JT, Austin PC, Alter DA, Ko DT. Effectiveness of public report cards for improving the quality of cardiac care: the EFFECT study: a randomized trial. JAMA. 2009 Dec 2;302(21):2330-7. doi: 10.1001/jama.2009.1731. Epub 2009 Nov 18.
PubMed 19923205Ahmad M, Schwalm JD, Velianou JL, Natarajan MK. Impact of routine in-hospital assessment of low-density lipoprotein levels and standardized orders on statin therapy in patients undergoing percutaneous coronary interventions. J Invasive Cardiol. 2005 Oct;17(10):518-20.
PubMed 16204743Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006 Jan 17;113(2):203-12. doi: 10.1161/CIRCULATIONAHA.105.505636. Epub 2006 Jan 9.
PubMed 16401776Hudson M, Richard H, Pilote L. Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap? Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):773-85. doi: 10.1002/pds.1414.
PubMed 17486661Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, Roger VL. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med. 2009 Oct;122(10):961.e7-13. doi: 10.1016/j.amjmed.2008.12.021. Epub 2009 Jun 26.
PubMed 19560749Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007 Jan 10;297(2):177-86. doi: 10.1001/jama.297.2.177.
PubMed 17213401Rublee DA, Chen SY, Mardekian J, Wu N, Rao P, Boulanger L. Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy. Am J Ther. 2012 Jan;19(1):24-32. doi: 10.1097/MJT.0b013e3181ee707e.
PubMed 20838204Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med. 2009 Feb 9;169(3):260-8. doi: 10.1001/archinternmed.2008.552.
PubMed 19204217
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- TAKEmeds Program: The Adherence and Knowledge Exchange Heart and Stroke Medicines Study
- ClinicalTrials.gov ID
- NCT02597205
- Acronym / sponsor ID
- TAKEmeds / 2014HHSC0016
- Conditions
- Myocardial Infarction
- Keywords
- Medical adherence, Lifestyle modification, Mobile Health, Secondary Prevention
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 190 participants (actual)
- Lead sponsor
- Duke Kunshan UniversityUniversity, hospital or other
- Collaborators
- Population Health Research Institute, Fudan University, Hainan Provincial Nongken General Hospital
- Study start
- May 2015
- Primary completion
- Dec 2015 (actual)
- Study completion
- Jun 2016 (actual)
- First posted
- 5 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overarching goal of this program to increase the use of evidence-based, secondary-prevention medications and promote healthy lifestyles among myocardial infarction (MI) patients through using provider-facing mobile app and patients-facing text messages.
Detailed description
Background:
Cardiovascular disease (CVD) affects half of all individuals over their lifetime.CVD is the leading cause of all non-communicable disease (NCD) deaths, and is projected to increase by 15% worldwide between 2010 and 2020. A wealth of evidence and international guidelines support the use of low-cost, evidence-based medication, for the management of established CVD.
Study aim:
- To develop and test the usability of a multifaceted, information-technology intervention among patients with a history of myocardial infarction (MI) and their healthcare providers.
- To develop, contextualize and assess the efficacy of patient-directed text messages as a means of improving medication adherence among myocardial Infraction patients in Shanghai, China.
- To test the usability and efficacy of text message reminders aimed at modifying major health risk behaviors including smoking and diet among MI patients.
Methods:
Study design overview:
This is a short-term, quasi-experimental, pre-post intervention study designed to evaluate the feasibility and effectiveness of using mobile phone app and text messaging as a means to improve adherence to medication for secondary prevention, promote behavior change, and reduce risk factors among MI patients.
Study setting and study team:
The study is going to be conducted in Shanghai and Haikou, Hainan, China. There are four academic collaborating institutions in this study: Global Health Research Center, Duke Kunshan University (DKU), China, Population Health Research Institution (PHRI), Canada and School of Public Health, Fudan University, China and Hainan Nongken General Hospital, China.
The DKU research team plays the leading role to design the study, develop the app and messages and oversee the entire implementation process. The PHRI research team will primarily work with the DKU research team on the physician-facing app and patient-facing messages development. The Fudan and Hainan research team will be responsible for local implementation.
Pre-intervention preparation:
Development of provider software application: To understand the actual needs and barriers that physicians face in using the app, the DKU research team will conduct assessment among physicians in the three community healthcare centers. The assessment is done through a short survey and key informant interview. Information from the survey and interviews will inform app design and development decisions.
Development of patient-centered message bank: The DKU research team will work with the PHRI research team to develop the message bank through literature review search. The message bank will cover five domains to help MI patients with medical adherence and lifestyle modification: 1) medical adherence; 2) diet; 3) exercise; 4) smoking cessation; 5) general heart health (see appendix 4 for the messages). To contextualize the messages and ensure its comprehensibility to patients, the Fudan and Hainan research team will invite physicians to validate the message (see appendix 5 for the message validation survey). Physicians will be asked to score each message in terms of its likability and comprehensibility. Two messages in each domain with the lowest score will be deleted. Considering that reading texts might be difficult for some patients, voice message option is also available for patients to choose. The contents of both the texts and voice messages are identical.
Intervention:
The study is designed to have two interventions targeting physicians and patients respectively. Only one community healthcare center will receive the intervention and the intervention period is designed to be 12 weeks. The Fudan and Hainan research team will be responsible for recruiting physicians and each physician will recruit MI patients to participate in the study. Physicians play dual role in this study: 1) as subjects who will use the app to prescribe medications and 2) as collaborators who will help recruit patients and collect their baseline data. The DKU research team will train the physicians how to use the app before they start to recruit patients.
- Provider-level intervention: Physicians will use the smart phone application, specifically designed for this study, to help them with medications prescription and patient recruitment. The prescription recommendations are based on the NICE (National Institute for Health and Care Excellence) guidelines 2014 in MI secondary prevention.
- Patient-level intervention:
Patients that are eligible to participate will receive automated, periodic evidence-based text messages about consistent medication use and lifestyle modification via text-messaging. They will receive standard ongoing care as well as regular unidirectional text messages via text or voice message over a 12 week period.
Process Evaluation:
Qualitative research methods will be used to obtain feedback from both the providers and the patients on the physician app and the short messaging system (SMS). To assess whether the intervention is implemented as planned and to gain their user feedback, the DKU, Fudan and Hainan research team will conduct phone and face-to-face interviews respectively in the middle and at the end of the intervention. All questions will be open-ended allowing participants to raise important issues even if they are not covered in our original topic guide. Four physicians and eight patients (two from each physician) will be invited to participate in the process evaluation interview. The mid-term evaluation (between 4-6 weeks after the intervention begins) are all one-on-one in-depth interviews. The final-term evaluation will consist of one focus group discussion among the four physicians and individual interviews to patients.
Data management and analysis:
Questionnaires require translation before coding and further data analysis can occur. In addition to coding and translation, interviews and focus groups will both be recorded and require transcription. All data entry will be performed by the Fudan and Hainan research team and will occur as close to the time of data collection to ensure accuracy.
Descriptive analysis will be used to describe the rate of adherence among the patients. Percentage differences in the proportion of patients who adhered to medication use and those who did not adhere to the medication use will be compared. Characteristics will be compared at baseline and after follow-up by using independent t tests for continuous variables (physical activity and diet) or chi-square tests for categorical variables (smoking status). Analyses will be performed using stata, version 12. Lastly, the interview and focus groups transcriptions will be coded for emerging themes using QSR Nvivo.
Risks and benefits:
This study offers participants the prospect of direct benefits: 1) it may potentially improve patient medical adherence; 2) it may potentially help patients build healthy lifestyle; 3) it may give guidance for physicians on evidence-based medicines prescription; 4) it may facilitate interactions between patients and physicians.
No foreseeable risks are anticipated for physicians. As for patients, one concern is that the exercise promotion messages, if taken without cautions, may to some degree increase the risk of heart attack for some patients. To eliminate this concern, the text messages suggest patients consult their doctors first before taking any exercise to reduce such risk to minimal. The risk of possible breach of confidentiality is addressed through using vigorous methods to protect the identity of subjects. After the data are collected, entered, and digitized, the investigators will store identifiable information in a separate data set and remove all such information from the main database (same to the information collected at the pre-intervention stage). The app will generate a unique identification number (ID) for each physician and patient for confidentiality use. Linkage will be through the study ID and performed only when necessary. Baseline and follow-up surveys will be linked by study ID only. As for the information collected on the app, they cannot be accessed without entering the password set by the physicians themselves. Only physicians, programmers and DKU research team members have access to it when necessary.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Mobile app | Experimental | Behavioral: physician-facing app and patient-facing messagesMulti-faceted intervention for physicians and patients respectively: physician-facing app and patient-facing messages |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Physicians who: 1) manage MI patients; 2) are interested in and consent to participate in this project; 3) have an Android-based smart phone;
- Patients who: 1) if they have suffered from a myocardial infraction; 2) they are physical and mentally able to manage their MI conditions; 3) they own a mobile telephone with the ability to read text messages or receive voice messages, and 4) willing to provide informed consent.
Key exclusion criteria (2 listed)
- Physicians who i) do not have an Android smart phone or not being able to use one; ii) do not managing MI patients; iii) current participating in another study.
- Patients who are: 1) not being able to use a cellphone; 2) severally ill; 3) current participating in another study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| physician-facing app and patient-facing messagesA physician-facing app was designed to help physicians with recruiting and managing patients and with evidence-based medications prescription. Messages were also developed to send to patients to improve their medical adherence and modify lifestyle. | Behavioural | Mobile app |
Primary outcome
Medical adherence change
Time frame: Three months
Score change measured by the well-validated 4-item Morisky Green Levine Scale
3 secondary outcomes
Change in diet
Time frame: Three months
Change in exercise
Time frame: Three months
Change in smoking habit
Time frame: Three months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2018.
- BackgroundSelected leading causes of death.: Statistics Canada; 2005.
- BackgroundGlobal Status Report on Non-Communicable Diseases 2010. Geneva World Health Organization; 2011.
- Background: PubMed 16461820Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006 Feb 14;113(6):791-8. doi: 10.1161/CIRCULATIONAHA.105.548206. Epub 2006 Feb 6.
- Background: PubMed 21074258Alwan A, Maclean DR, Riley LM, d'Espaignet ET, Mathers CD, Stevens GA, Bettcher D. Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries. Lancet. 2010 Nov 27;376(9755):1861-8. doi: 10.1016/S0140-6736(10)61853-3. Epub 2010 Nov 10.
- Background: PubMed 11723030Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001 Nov 27;104(22):2746-53. doi: 10.1161/hc4601.099487.
- Background: PubMed 19620271Lee DS, Chiu M, Manuel DG, Tu K, Wang X, Austin PC, Mattern MY, Mitiku TF, Svenson LW, Putnam W, Flanagan WM, Tu JV; Canadian Cardiovascular Outcomes Research Team. Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors. CMAJ. 2009 Aug 4;181(3-4):E55-66. doi: 10.1503/cmaj.081629. Epub 2009 Jul 20.
- Background: PubMed 21872920Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011 Oct 1;378(9798):1231-43. doi: 10.1016/S0140-6736(11)61215-4. Epub 2011 Aug 26.
- Background: PubMed 19923205Tu JV, Donovan LR, Lee DS, Wang JT, Austin PC, Alter DA, Ko DT. Effectiveness of public report cards for improving the quality of cardiac care: the EFFECT study: a randomized trial. JAMA. 2009 Dec 2;302(21):2330-7. doi: 10.1001/jama.2009.1731. Epub 2009 Nov 18.
- Background: PubMed 16204743Ahmad M, Schwalm JD, Velianou JL, Natarajan MK. Impact of routine in-hospital assessment of low-density lipoprotein levels and standardized orders on statin therapy in patients undergoing percutaneous coronary interventions. J Invasive Cardiol. 2005 Oct;17(10):518-20.
- Background: PubMed 16401776Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006 Jan 17;113(2):203-12. doi: 10.1161/CIRCULATIONAHA.105.505636. Epub 2006 Jan 9.
- Background: PubMed 17486661Hudson M, Richard H, Pilote L. Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap? Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):773-85. doi: 10.1002/pds.1414.
- Background: PubMed 19560749Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, Roger VL. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med. 2009 Oct;122(10):961.e7-13. doi: 10.1016/j.amjmed.2008.12.021. Epub 2009 Jun 26.
Related trials for Myocardial Infarction
RecruitingPhase 4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
ST Elevation Myocardial Infarction
Not yet recruitingPhase 4
Capital Offload-Shock
Hypervolemia, Cardiogenic Shock
Recruiting
ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
Myocardial Infarction (MI), Sudden Cardiac Death Due to Cardiac Arrhythmia
Recruiting
CRP Apheresis in Infarct-Related Cardiogenic Shock
Cardiogenic Shock, Acute Myocardial Infarction (AMI)
RecruitingObservational study
Breisgau PHENO-HEART MI
Myocardial Infarction, STEMI
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
JD Schwalm, MD principal investigator
Population Health Research Institute, Hamilton Health Sciences Corporation, Canada
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing physician-facing app and patient-facing messages in people with Myocardial Infarction, run by Duke Kunshan University at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Medical adherence change (time frame: Three months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02597205, which also lists 16 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2018.